Recovery · Investigational
Chrysalin (TP508)
No lawful US pathway
01 · Overview
Chrysalin, also known as TP508 or rusalatide acetate, is a 23-amino acid synthetic peptide representing a portion of the receptor-binding domain of human thrombin (PMID 17079379). It is designed to act on cell surface receptors on fibroblasts and other cells to stimulate healing events including inflammatory cell recruitment, cell migration and proliferation, matrix formation, and new blood vessel growth (PMID 17079379).
Preclinical studies showed accelerated healing of skin wounds and fractures in animals (PMID 17079379).
02 · Research summary & key findings
In a 60-subject randomized, placebo-controlled phase I/II trial in diabetic foot ulcers, topical Chrysalin more than doubled the incidence of complete healing and shortened time to closure, with adverse events similar to placebo (PMID 17244316). In a large phase III trial in distal radius fractures, it accelerated radiographic healing but failed its primary clinical endpoint, time to removal of immobilization, in the intent-to-treat population, meeting it only in a subset of osteopenic women (PMID 18803458). It has not been approved.
03 · Regulatory status
Chrysalin (TP508) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Chrysalin (TP508) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 3 FDA-approved compounds in Recovery
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Chrysalin (TP508) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Topical
- Subcutaneous injection
References
- [1]Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues J Bone Joint Surg Am, 2006. PMID 17079379
- [2]Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study Wound Repair Regen, 2007. PMID 17244316
- [3]Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? Expert Opin Pharmacother, 2008. PMID 18803458
Primary literature
- PubMed: "Chrysalin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Chrysalin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Chrysalin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Recovery
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.